Acadia Pharmaceuticals Inc. ACAD
17.83 USD -0.49 (-2.67%)
Regular-session close
17.92 +0.09 +0.50%
Pre-market · Nov 19, 7:54 AM ET
17.83 Day range 18.49
15.86 52-week range 30.96
- YTD
- -33.25%
- 1 year
- -25.08%
News
benzinga.com Oppenheimer Maintains Perform on Acadia Pharmaceuticals, Lowers Price Target to $21 Oppenheimer analyst Matthew Hershenhorn maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Perform and lowers the price target from $23 to $21.
marketbeat.com ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge ACADIA Pharmaceuticals NASDAQ: ACAD is pursuing growth from its DAYBUE and NUPLAZID franchises while advancing neurological and psychiatric drug candidates and looking for external deals, CEO…
seekingalpha.com Acadia Pharmaceuticals Inc. (ACAD) Presents at UBS Global Biopharma Conference 2026 Transcript Acadia Pharmaceuticals Inc. (ACAD) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com Acadia Pharma Presents Additional Data From Phase 2 RADIANT Trial Evaluating Remlifanserin For Treatment Of Hallucinations And Delusions Associated With ADP, At 2026 CTAD Conference − New analyses show a consistent efficacy signal with once-daily 60 mg remlifanserin across multiple measures of psychosis, with larger estimated treatment effects with increasing baseline psychosis…
businesswire.com Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today presented additional data from the Phase 2 RADIANT trial evaluating remlifanserin for the treatment of hallucinations and…
benzinga.com Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
businesswire.com Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it has entered into an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569),…benzinga.com Morgan Stanley Maintains Equal-Weight on Acadia Pharmaceuticals, Lowers Price Target to $24 Morgan Stanley analyst Jeffrey Hung maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and lowers the price target from $28 to $24.
defenseworld.net ACADIA Pharmaceuticals Inc. $ACAD Shares Purchased by Allspring Global Investments Holdings LLC Allspring Global Investments Holdings LLC lifted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 35.1% during the third quarter, according to the company in its most recent…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…benzinga.com Canaccord Genuity Maintains Buy on Acadia Pharmaceuticals, Raises Price Target to $38 Canaccord Genuity analyst Sumant Kulkarni maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $36 to $38.
benzinga.com DraftKings Posts Downbeat Q3 Results, Joins Atlassian, Natera And Other Big Stocks Moving Lower In Friday’s Pre-Market Session Stock futures mixed as DraftKings plunged 21% after earnings missed estimates and FY26 guidance was cut; several other stocks also fell premarket.benzinga.com RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Raises Price Target to $38 RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $36 to $38.
benzinga.com ACADIA Pharmaceuticals Q3 2026 Earnings Call Transcript ACADIA Pharmaceuticals (NASDAQ:ACAD) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com ACADIA Pharmaceuticals Narrows FY2026 Sales Guidance from $1.240B-$1.300B to $1.265B-$1.295B vs $1.272B Est ACADIA Pharmaceuticals (NASDAQ:ACAD) narrows FY2026 sales outlook from $1.240 billion-$1.300 billion to $1.265 billion-$1.295 billion vs $1.272 billion estimate.
benzinga.com Needham Reiterates Buy on Acadia Pharmaceuticals, Maintains $35 Price Target Needham analyst Ami Fadia reiterates Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $35 price target.
